Breaking News, Financial News

Genzyme

During the quarter, the company ceased fill/finish operations at its Allston facility for products sold in the U.S.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Genzyme 4Q Revenues: $1.2 billion (+23%) 4Q Earnings: $471.9 million (earnings were $23.2 million 4Q10) FY Revenues: $4.0 billion (+2%) FY Earnings: $422.1 million (flat) Comments: During the quarter, the company ceased fill/finish operations at its Allston facility for products sold in the U.S. According to the company, the recovery of Cerezyme supply is on track, and Fabrazyme supply is improving with allocations up 82% from the third to fourth quarter. Cerezyme sales in the qu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters